Biomarker Diagnostic for Crohn's Disease Severity

There are approximately 1.8 million people suffering from Crohn's disease in the US and Europe. A portion of these will require aggressive treatment, such as surgical resections and biologics.

Upstate has identified a novel mutant fusion mRNA that allows easy and definitive identification of a subset of Crohn's Disease patients that is highly likely to require such agressive treatment. In fact, 2/3rds of those harboring the mutant fusion mRNA required at least one surgical resection and the use of biologics, 56% required more than one resection, and 22% suffered IBD related neoplasia. The fusion mRNA can be detected using a variety of methods to create an easy to use assay for gastroenterologists.

Patent Information:
Technology/Start-up ID: